<<
>>

Pancreatic polypeptidoma

GI NETs secreting pancreatic polypeptide have been de­scribed in humans.30 Although not yet associated with a dis­tinct clinical syndrome, watery diarrhea, diabetes mellitus, weight loss, decreased gastric acid secretion, peptic ulceration, flushing, rashes, and acute psychosis have been described in human patients with a pancreatic polypeptidoma.30

Only one dog with a suspected pancreatic polypeptidoma has been reported in the veterinary literature.33 This dog presented for chronic vomiting, anorexia, weight loss, and lethargy.

A concurrent insulinoma was diagnosed on the basis of hypo­glycemia in the face of a high serum insulin concentration. Baseline serum gastrin concentration was seven-times the up­per limit of the reference range, but did not rise after secretin or calcium challenge. Serum pancreatic polypeptide concen­tration was 3,500-times the upper limit of the reference range. Multiple pancreatic tumors removed at exploratory laparot­omy showed a strongly positive immunoreactivity for pan­creatic polypeptide and a positive reaction for insulin, but no reaction for gastrin or other GI regulatory peptides. It should, however, be noted that approximately 75% of NETs of the GI tract stain positive for pancreatic polypeptide, although the clinical syndrome in these patients is caused by other neuro­endocrine substances.33 Thus, it remains uncertain whether there truly was a cause-effect relationship between the ex­tremely high serum pancreatic polypeptide concentration and the clinical signs observed in this patient.

9.4.6

<< | >>
Source: Steiner J.M. (ed.). Small Animal Gastroenterology. Schluetersche,2008. — 387 p.. 2008

More on the topic Pancreatic polypeptidoma: